|
| 37194094 | Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis. | Arthritis Res Ther | 2023 |
| 35146532 | Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. | Acta Derm Venereol | 2022 |
| 32770640 | Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. | Arthritis Rheumatol | 2021 |
| 34481517 | Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. | Arthritis Res Ther | 2021 |
| 31957970 | Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. | ACR Open Rheumatol | 2020 |
| 31174584 | Spinal radiographic progression over 2Â years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. | Arthritis Res Ther | 2019 |
| 29860356 | Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. | Rheumatology (Oxford) | 2019 |
| 29458278 | Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis. | Scand J Rheumatol | 2018 |
| 30121827 | Efficacy and Safety of Secukinumab 150Â mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study. | Rheumatol Ther | 2018 |
| 27965257 | Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. | Ann Rheum Dis | 2017 |
| 28217871 | Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study. | Arthritis Rheumatol | 2017 |
| 28235249 | Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. | Arthritis Care Res (Hoboken) | 2017 |
| 29435364 | Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. | RMD Open | 2017 |
| 29138986 | Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study. | Rheumatol Ther | 2017 |
| 27582421 | Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. | Ann Rheum Dis | 2017 |
| 27014997 | Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. | Arthritis Rheumatol | 2016 |
| 27390130 | Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1). | Arthritis Rheumatol | 2016 |
| 26834211 | Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study. | J Rheumatol | 2016 |
| 26135703 | Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2015 |
| 26422723 | Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. | N Engl J Med | 2015 |
| 26699169 | Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. | N Engl J Med | 2015 |
| 24429175 | One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. | J Rheumatol | 2014 |
| 24330415 | Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study. | J Eur Acad Dermatol Venereol | 2014 |
| 22730366 | Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. | Ann Rheum Dis | 2013 |
| 23106107 | Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. | Br J Dermatol | 2013 |
| 19144150 | Increased expression of FcgammaRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus. | Arthritis Res Ther | 2009 |
| 18795942 | Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. | Clin Exp Immunol | 2008 |
| 17265494 | Autoantibodies to RNA helicase A: a new serologic marker of early lupus. | Arthritis Rheum | 2007 |
| 17968925 | Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. | Arthritis Rheum | 2007 |
| 16948135 | Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. | Arthritis Rheum | 2006 |
| 16846524 | Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. | Arthritis Res Ther | 2006 |
| 16890891 | Urinary biomarkers in lupus nephritis. | Autoimmun Rev | 2006 |
| 15698448 | Circulating endothelial cells are associated with future vascular events in hemodialysis patients. | Kidney Int | 2005 |
| 16126984 | The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. | Ann N Y Acad Sci | 2005 |
| 16126005 | Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. | Clin Immunol | 2005 |
| 16214093 | Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. | Autoimmun Rev | 2005 |
| 16177126 | Induction of apoptosis by the hydrocarbon oil pristane: implications for pristane-induced lupus. | J Immunol | 2005 |
| 16175928 | High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. | Lupus | 2005 |
| 16142863 | Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. | J Rheumatol | 2005 |
| 15996187 | Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors. | Clin Exp Immunol | 2005 |
| 15373921 | Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. | Clin Exp Immunol | 2004 |
| 15596633 | Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting. | Arch Intern Med | 2004 |
| 15188361 | Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. | Arthritis Rheum | 2004 |
| 12911539 | Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus. | Kidney Int | 2003 |
| 12209530 | Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice. | Arthritis Rheum | 2002 |
| 11737591 | Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. | Kidney Int | 2001 |
| 11678452 | Titration emulation: a computer-assisted technique that simplifies the quantification of anti-dsDNA antibodies using the Crithidia luciliae assay. | Lupus | 2001 |
| 11665978 | Increased prevalence of autoantibodies to ku antigen in African American versus white patients with systemic lupus erythematosus. | Arthritis Rheum | 2001 |
| 11125477 | B cell subsets in pristane-induced autoimmunity. | Curr Top Microbiol Immunol | 2000 |
| 10931159 | Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. | Clin Exp Immunol | 2000 |